Abstract：Objective To study the efficacy and safety of caffeine used in the early (≤ 72 hours after birth) and late (>72 hours after birth) stage in preterm infants with a gestational age of ≤ 31 weeks. Methods A retrospective analysis was performed for 640 preterm infants (with a gestational age of ≤ 31 weeks) who were admitted to the neonatal intensive care unit of eight hospitals in Jiangsu Province, China. Of the 640 preterm infants, 510 were given caffeine in the early stage (≤ 72 hours after birth; early use group) and 130 were given caffeine in the late stage (>72 hours after birth; late use group). The clinical data were compared between the two groups. Results There were no significant differences in birth weight, Apgar score, sex, gestational age, and age on admission between the two groups (P > 0.05). Compared with the late use group, the early use group had a significantly younger age at the beginning and withdrawal of caffeine treatment (P < 0.05) and a significantly shorter duration of caffeine treatment (P < 0.05). There was no significant difference in respiratory support on admission between the two groups (P > 0.05). Compared with the late use group, the early use group had significantly lower incidence rate of apnea (P < 0.05) and significantly shorter oxygen supply time and length of hospital stay (P < 0.05). There were no significant differences between the two groups in the incidence rates of neonatal intracranial hemorrhage, periventricular leukomalacia, necrotizing enterocolitis, retinopathy of prematurity, and patent ductus arteriosus at discharge and NBNA score at the corrected gestational age of 40 weeks (P > 0.05). However, significant differences were found in the incidence of bronchopulmonary dysplasia and the rate of home oxygen therapy, but there was no significant difference in the mortality rate between the two groups (P > 0.05). Conclusions Early use of caffeine can shorten the duration of caffeine treatment, oxygen supply time, and length of hospital stay, with little adverse effect, in preterm infants with a gestational age of ≤ 31 weeks.
YANG Yang,CHENG Rui,WU Qi et al. Safety and efficacy of caffeine use started at different time in preterm infants: a multicenter study in Jiangsu Province, China[J]. CJCP, 2020, 22(2): 130-135.
Donda K, Vijayakanthi N, Dapaah-Siakwan F, et al. Trends in epidemiology and outcomes of respiratory distress syndrome in the United States[J]. Pediatr Pulmonol, 2019, 54(4):405-414.
[2]
Kalikkot Thekkeveedu R, Guaman MC, Shivanna B. Bronchopulmonary dysplasia:a review of pathogenesis and pathophysiology[J]. Respir Med, 2017, 132:170-177.
[3]
Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome-2016 update[J]. Neonatology, 2017, 111(2):107-125.
[4]
Wielenga JM, van den Hoogen A, van Zanten Henriette A, et al. Protocolized versus non-protocolized weaning for reducing the duration of invasive mechanical ventilation in newborn infants[J]. Cochrane Database Syst Rev, 2016, 3:CD011106.
[5]
Steer P, Flenady V, Shearman A, et al. High dose caffeine citrate for extubation of preterm infants:a randomised controlled trial[J]. Arch Dis Child Fetal Neonatal Ed, 2004, 89(6):F499-F503.
[6]
Katheria AC, Sauberan JB, Akotia D, et al. A pilot randomized controlled trial of early versus routine caffeine in extremely premature infants[J]. Am J Perinatol, 2015, 32(9):879-886.
[7]
Dobson NR, Patel RM, Smith PB, et al. Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants[J]. J Pediatr, 2014, 164(5):992-998.
[8]
Taha D, Kirkby S, Nawab U, et al. Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants[J]. J Matern Fetal Neonatal Med, 2014, 27(16):1698-1702.
[9]
Nagasato A, Nakamura M, Kamimura H. Comparative study of the efficacy and safety of caffeine and aminophylline for the treatment of apnea in preterm infants[J]. Yakugaku Zasshi, 2018, 138(2):237-242.
[10]
Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity[J]. N Engl J Med, 2006, 354(20):2112-2121.
[11]
Schmidt B, Anderson PJ, Doyle LW, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity[J]. JAMA, 2012, 307(3):275-282.
[12]
Kassim Z, Greenough A, Rafferty GF. Effect of caffeine on respiratory muscle strength and lung function in prematurely born ventilated infants[J]. Eur J Pediatr, 2009, 168(12):1491-1495.
Torchin H, Combarel D, Aubelle MS, et al. Association of serum angiogenic factors with bronchopulmonary dysplasia. The ANGIODYS cohort study[J]. Pregnancy Hypertens, 2019, 18:82-87.
[15]
Naeem A, Ahmed I, Silveyra P. Bronchopulmonary dysplasia:an update on experimental therapeutics[J]. Eur Med J (Chelmsf), 2019, 4(1):20-29.
Hand I, Zaghloul N, Barash L, et al. Timing of caffeine therapy and neonatal outcomes in preterm infants:a retrospective study[J]. Int J Pediatr, 2016, 2016:9478204.
[18]
Álvarez-Fuente M, Moreno L, Mitchell JA, et al. Preventing bronchopulmonary dysplasia:new tools for an old challenge[J]. Pediatr Res, 2019, 85(4):432-441.
[19]
Mueni E, Opiyo N, English M. Caffeine for the management of apnea in preterm infants[J]. Int Health, 2009, 1(2):190-195.
Lodha A, Entz R, Synnes A, et al. Early caffeine administration and neurodevelopmental outcomes in preterm infants[J]. Pediatrics, 2019, 143(1). pii:e20181348.
[22]
Moya FR, Mazela J, Shore PM, et al. Prospective observational study of early respiratory management in preterm neonates less than 35 weeks of gestation[J]. BMC Pediatr, 2019, 19(1):147.
[23]
Belkhatir K, Zivanovic S, Lumgair H, et al. Variations in preterm stabilisation practices and caffeine therapy between two European tertiary level neonatal units[J]. Acta Paediatr, 2019. doi:10.1111/apa.15011[Epub ahead of print].
[24]
Park HW, Lim G, Chung SH, et al. Early caffeine use in very low birth weight infants and neonatal outcomes:a systematic review and meta-analysis[J]. J Korean Med Sci, 2015, 30(12):1828-1835.
[25]
Scanlon JE, Chin KC, Morgan ME, et al. Caffeine or theophylline for neonatal apnoea?[J]. Arch Dis Child, 1992, 67(4 Spec No):425-428.
[26]
Skouroliakou M, Bacopoulou F, Markantonis SL. Caffeine versus theophylline for apnea of prematurity:a randomised controlled trial[J]. J Paediatr Child Health, 2009, 45(10):587-592.
[27]
Zulqarnain A, Hussain M, Suleri KM, et al. Comparison of caffeine versus theophylline for apnea of prematurity[J]. Pak J Med Sci, 2019, 35(1):113-116.
[28]
Welsh C, Pan J, Belik J. Caffeine impairs gastrointestinal function in newborn rats[J]. Pediatr Res, 2015, 78(1):24-28.
Hwang J, Kim YS, Shin JH, et al. Hemodynamic effects on systemic blood flow and ductal shunting flow after loading dose of intravenous caffeine in preterm infants according to the patency of ductus arteriosus[J]. J Korean Med Sci, 2018, 33(4):e25.
[31]
Gupte AS, Gupta D, Ravichandran S, et al. Effect of early caffeine on neurodevelopmental outcome of very low-birth weight newborns[J]. J Matern Fetal Neonatal Med, 2016, 29(8):1233-1237.
[32]
Fleiss B, Gressens P. Neuroprotection of the preterm brain[J]. Handb Clin Neurol, 2019, 162:315-328.
[33]
Atik A, Harding R, De Matteo R, et al. Caffeine for apnea of prematurity:effects on the developing brain[J]. Neurotoxicology, 2017, 58:94-102.
